Home › Finerenone Cuts Deaths in Mid-Stage Trial
 

Keywords :   


Finerenone Cuts Deaths in Mid-Stage Trial

2015-09-01 05:16:57| Chemicals - Topix.net

Promising data from an exploratory phase IIb trial of finerenone , an oral, nonsteroidal mineralocorticoid receptor antagonist , have been presented at the European Society of Cardiology Congress 2015 in London. The ARTS-HF study investigated the effects of different dosages of finerenone compared with eplerenone in patients with worsening chronic heart failure with a reduced ejection fraction as well as type-2 diabetes mellitus and/or chronic kidney disease.

Tags: trial cuts deaths

Category:Chemicals

Latest from this category

All news
04.11Registration Open for 2025 Waterborne Symposium
04.11ROSS Ribbon Blenders Provide Safe, Efficient Bulk Blending
04.11U.S. Green Building Council Announces 2024 Leadership Award Recipients
04.11ASTM International Publishes New Standards for FT4 Powder Rheometer Procedures
04.11Nippon Paint Marine Uses Biomimetics to Unlock Next Generation in Hull Coatings
04.11AkzoNobels Yacht Brands Lead the Way in Digital Training and Support
02.11Weekly Recap: Nippon Paint, AkzoNobel, PPG Top This Weeks Stories
01.11BASF TotalEnergies Petrochemicals Receives United Way Champions of Hope Award
Chemicals »
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 7
05.11Tropical Storm Rafael Public Advisory Number 7
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 7
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
More »